Advances in type 1 diabetes technology give people with the condition and their caregivers a little more freedom in their ...

McEvoy, the former leader of Johnson & Johnson’s medtech business, started immediately. Jim Hollingshead, who was CEO of ...

Receiving FDA clearance would allow Medtronic to pair its pumps with a glucose monitor being developed for the company by ...

FDA clearance would allow Medtronic to integrate the device with Abbott's continuous glucose monitoring sensor, advancing the companies' partnership.

Tandem Diabetes Care, Inc.’s TNDM impressive international expansion is expected to bolster growth in the upcoming quarters. A robust diabetes market provides a favorable opportunity for the company’s ...

The Infusion Pump Market is valued at USD 14257.99 Million in 2022 and is expected to reach USD 27383.94 Million by 2030 at a ...

The Global Insulin Pump Market achieved a valuation of $5.90 Billion in 2024 and is anticipated to exceed $14.49 Billion by 2035, reflecting a compounded annual growth rate (CAGR) of 8.55% during the ...

It's a great strategy, but it's essential to avoid those companies that only look undervalued but actually aren't. Some stocks are lagging the market for good reasons -- because their businesses look ...

Tandem Diabetes Care, Inc. is a medical device company dedicated ... Tandem's flagship product, the t:slim X2™ insulin pump, is capable of remote software updates using a personal computer ...

Tandem Diabetes Care, Inc. TNDM shares soared 7.6% in the ... the company’s reported sales grew by a staggering 44%, while worldwide pump shipments increased by more than 25%.

Tandem Diabetes Care, Inc. TNDM shares soared 7.6% in the last trading session to close at $17.61. The move was backed by solid volume with far more shares changing hands than in a normal session.